3B BlackBio Dx FY26: Revenue up 47% to ₹142 cr

Key FY26 takeaway for investors

3B BlackBio Dx Ltd (BSE: 532067) reported a strong FY26 on a consolidated basis, with revenue from operations rising to ₹141.92 crore from ₹96.47 crore in FY25. Profit after tax (PAT) increased to ₹59.93 crore from ₹47.69 crore, and basic EPS moved up to ₹69.94 from ₹55.66. The year’s performance was closely linked to the company’s Molecular Diagnostics (MDx) business and the contribution from its acquired subsidiary, Coris BioConcept (also referenced in some notes as Chorus BioConcert). At the same time, quarter-on-quarter (QoQ) volatility and margin compression in Q4 FY26 drew attention to cost control and the role of other income.

FY26 consolidated results: revenue, PAT, EPS

The company’s audited results for the year ended March 31, 2026 show consolidated revenue from operations of ₹141.92 crore, up 47.1% year-on-year from ₹96.47 crore. Consolidated PAT rose to ₹59.93 crore, a 25.7% increase from ₹47.69 crore. Consolidated profit before tax (PBT) increased to ₹76.97 crore from ₹64.00 crore. Basic EPS for FY26 came in at ₹69.94, compared with ₹55.66 in FY25.

Some summaries also described the year as having consolidated revenue of about ₹142 crore and PAT of nearly ₹160 crore. The audited consolidated PAT figure stated in the results is ₹59.93 crore.

Q4 FY26: strong YoY growth, weaker sequential trend

For the quarter ended March 31, 2026, consolidated revenue from operations was ₹35.43 crore versus ₹22.50 crore a year ago. Consolidated PAT for Q4 FY26 stood at ₹9.80 crore compared with ₹8.04 crore in Q4 FY25, and Q4 EPS increased to ₹11.44 from ₹9.38.

However, multiple performance summaries highlighted a sharp QoQ decline in Q4 versus Q3. Reported Q4 revenue from operations of ₹35.43 crore was down 29.62%-29.63% QoQ from ₹50.35 crore in Q3 FY26. Q4 PAT of ₹9.56 crore in one snapshot was described as down 56.01% QoQ (while also up 13.81% YoY versus ₹8.40 crore). These sequential moves were framed as signs of revenue volatility and pressure on profitability.

Standalone numbers: modest revenue growth, profit dip in Q4

On a standalone basis, Q4 FY26 revenue from operations was ₹24.63 crore versus ₹23.02 crore in Q4 FY25. Standalone Q4 net profit was ₹7.45 crore compared with ₹9.24 crore a year earlier. For the full year FY26, standalone revenue from operations was ₹97.28 crore compared with ₹90.53 crore in FY25.

Management commentary also indicated that standalone revenue growth has slowed to about 2% to 3% year-on-year for the last two quarters, compared to earlier growth rates of 15% to 20%.

Molecular Diagnostics remains the core growth driver

The company identified Molecular Diagnostics as the key driver of growth. MDx revenue from operations increased to ₹131.12 crore in FY26 from ₹84.28 crore in FY25. Within this FY26 MDx figure, Coris sales were included at ₹35.91 crore. The UK subsidiary, TRUPCR Europe Limited, contributed ₹20.67 crore in sales.

Exports within MDx rose to ₹21.41 crore from ₹17.04 crore, supporting the company’s claim of building international momentum even as competition rises.

Coris BioConcept contribution to consolidated performance

The acquisition of Coris BioConcept was described as a meaningful contributor to FY26 consolidated revenue and profitability. The subsidiary reported sales of ₹35.91 crore and PAT of ₹8.76 crore. Company notes also described the integration as supporting the jump in consolidated revenue and profit.

This matters because the FY26 revenue step-up was not only a domestic story. The consolidated numbers embed additional international revenue streams through Coris and TRUPCR Europe.

India MDx market: growth, share, and what slowed in FY26

The molecular diagnostic business in India was described as having grown by about 10%, with sales increasing from ₹78.34 crore to ₹86.47 crore. Management also stated the total addressable market for MDx in India at ₹500-₹600 crore, and estimated its market share at around 15%.

Growth in the Indian molecular diagnostic business was said to be slightly below projections due to exceptional flu and chikungunya demand in FY25, and due to geopolitical tensions in the Middle East affecting some conditions. The company also cited a moderation in standalone growth in recent quarters.

Margins, other income, and employee cost focus in Q4

A separate operating snapshot of Q4 FY26 highlighted margin compression. The operating margin (excluding other income) was reported at 23.96% in Q4 FY26 versus 43.14% in the prior quarter, while PAT margin was reported at 27.66% versus 44.57%.

Other income was a notable talking point, reported at ₹10.15 crore and described as 69.28% of profit before tax in Q4 FY26. Employee costs were also flagged as rising sharply, consuming 26.42% of revenues in that quarter, raising questions in that commentary about cost management.

Dividend and shareholder returns

The Board of Directors recommended a final dividend of 50%, translating to ₹5 per equity share of face value ₹10, subject to shareholder approval. The dividend recommendation came alongside the publication of audited results for the quarter and year ended March 31, 2026.

Summary table: FY26 and Q4 FY26 highlights

Outlook for FY27: management guidance versus industry growth

For FY2026-27 (FY27), management guided for overall growth of 15% to 20% when considering both domestic and export sales for 3B India, supported by broader products and new panels. Industry growth expectations for MDx in India were stated at 8% to 10% CAGR. The combination of a 15% market share estimate and a 15% to 20% growth target signals an intent to outgrow the broader category, assuming execution and demand hold up.

Market impact: what the numbers imply

The FY26 results show a clear top-line step-up and improved annual profitability, with revenue from operations up 47.1% and PAT up 25.7% on a consolidated basis. Segment disclosure underlines that MDx is driving most of the revenue base, and that acquisition-led consolidation has materially changed the scale. But Q4 commentary pointing to QoQ revenue decline and margin compression suggests investors are likely to track the quality of earnings, the reliance on other income in quarterly profitability, and the sustainability of operating margins.

Conclusion

3B BlackBio Dx closed FY26 with consolidated revenue of ₹141.92 crore and PAT of ₹59.93 crore, supported by MDx growth and the Coris BioConcept contribution. The Q4 pattern combined strong year-on-year growth with weaker sequential profitability and margin compression in some summaries. The next key monitorable is execution against management’s FY27 growth guidance of 15% to 20%, particularly across exports, partnerships, and the expanding MDx product portfolio.